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Accurate ante mortem diagnosis in frontotemporal lobar degeneration (FTLD) is
crucial to the development and implementation of etiology-based therapies. Several
neurodegenerative disease-associated proteins, including the major protein constituents
of inclusions in Alzheimer’s disease (AD) associated with amyloid-beta (Aβ1−42) plaque
and tau neurofibrillary tangle pathology, can be measured in cerebrospinal fluid (CSF) for
diagnostic applications. Comparative studies using autopsy-confirmed samples suggest
that CSF total-tau (t-tau) and Aβ1 42 levels can accurately distinguish FTLD from AD, with−
a high t-tau to Aβ1 42 ratio diagnostic of AD; however, there is also an urgent need for−
FTLD-specific biomarkers. These analyteswill require validation in large autopsy-confirmed
cohorts and face challenges of standardization of within- and between-laboratory sources
of error. In addition, CSF biomarkers with prognostic utility and longitudinal study of
CSF biomarker levels over the course of disease are also needed. Current goals in the
field include identification of analytes that are easily and reliably measured and can be
used alone or in a multi-modal approach to provide an accurate prediction of underlying
neuropathology for use in clinical trials of disease modifying treatments in FTLD. To
achieve these goals it will be of the utmost importance to view neurodegenerative disease,
including FTLD, as a clinicopathological entity, rather than exclusively a clinical syndrome.
Keywords: cerebrospinal fluid, biomarker, tau, Aβ1−42, frontotemporal dementia, primary progressive aphasia,
Alzheimer’s disease
INTRODUCTION
Most neurodegenerative diseases are characterized by specific
abnormally-modified protein aggregates, with resulting neuronal
cell loss and gliosis. The gold standard for diagnosis is micro-
scopic examination at autopsy; however, there is considerable
variability of clinical manifestations associated with underlying
Abbreviations: FTLD, frontotemporal lobar degeneration; AD, Alzheimer’s dis-
ease; Aβ, amyloid-beta; CSF, cerebrospinal fluid; CNS, central nervous system;
FTLD-tau, FTLD with tau pathology; TDP-43, TAR DNA binding protein-43;
FTLD-TDP, FTLD with TDP pathology; PiD, Pick’s disease; CBD, corticobasal
degeneration; PSP, progressive supranuclear palsy; pathogenic MAPT mutations-
FTDP-17, FTD and parkinsonism linked to chromosome 17; ALS, amyotrophic
lateral sclerosis; FUS, fused-in-sarcoma protein; FTLD-FUS, FTLD with FUS
pathology; FTLD-UPS, FTLD with tau- and TDP-43-negative ubiquitinated inclu-
sions; FTLD-ni, FTLD in the absence of significant neuropathological inclu-
sions; GRN, progranulin gene; MAPT, tau gene; C9orf72, C9orf72 gene; VCP,
valosin-containing protein gene; TARDBP, TDP-43 gene; FTLD-ALS, clinical
FTLD with ALS; CHMP2B, charged mutlivesciular body protein 2B gene; bvFTD,
behavioral-variant frontotemporal dementia; PPA, primary progressive aphasia;
lvPPA, logopenic-variant PPA; svPPA, semantic-variant PPA; naPPA, non-fluent
aggramatic variant PPA; CBS, corticobasal syndrome; Aβ1−42, β-amyloid; MCI,
mild cognitive impairment; t-tau, total-tau; p-tau, phosphorylated-tau; p-tau181,
phosphorylated tau at serine 181; p-tau231, phosphorylated tau at threonine 231;
ELISA, enzyme-linked immunosorbent assay; xMAP, luminex flow immunoas-
say; MRI, magnetic resonance imaging; DIAN, dominantly-inherited AD network;
MTBD, microtubule-binding domain; DTI, diffusion-tensor imaging; GM, gray
matter; GWAS, genome-wide association studies.
neuropathological diagnoses, as clinical symptoms most often
reflect the regional burden of pathology within the central ner-
vous system (CNS) rather than the specific underlying pro-
teinopathy. This is especially true in the heterogeneous family of
frontotemporal lobar degeneration (FTLD) clinical syndromes.
Two main pathologic FTLD subtypes exist (Figures 1A, 2):
cases with inclusions formed from the microtubule-binding pro-
tein tau (FTLD-tau) and those with TAR DNA binding protein-
43 (TDP-43) pathology (FTLD-TDP) (Mackenzie et al., 2010).
FTLD-tau includes the following tauopathies (Figures 2A–D):
Pick’s disease (PiD), corticobasal degeneration (CBD), progres-
sive supranuclear palsy (PSP), FTD and parkinsonism linked
to chromosome 17 (pathogenic MAPT mutations; FTDP-17),
and unclassifiable tauopathies (Mackenzie et al., 2010). FTLD-
TDP (Figures 2E–G) can be subdivided into four subtypes (A–D)
based on the morphology and distribution of lesions (Mackenzie
et al., 2011) and can also be associated with TDP-43 inclu-
sions in the anterior horn of the spinal cord and gliosis of the
corticospinal tracts, suggesting a continuum of FTLD with amy-
otrophic lateral sclerosis (ALS; FTLD-ALS) (Geser et al., 2008,
2009). A smaller number of FTLD cases are associated with
inclusions of another DNA-binding protein, fused-in-sarcoma
protein (FUS; FTLD-FUS), or other rare, less-defined patholo-
gies (FTLD-UPS, FTLD-ni) (Mackenzie et al., 2010). The major
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FIGURE 1 | Clinicopathological and genetic associations in FTLD.
(A) Neuropathological classification of FTLD-tau and FTLD-TDP subtypes
(PSP, progressive supranuclear palsy; CBD, corticobasal degeneration; PiD,
Pick’s disease; FTDP17, frontotemporal dementia with Parkinsonism linked to
chromosome 17; Tauopathy NOS, unclassifiable tauopathy; Subtypes A–D,
morphological subtypes of FTLD-TDP; ALS-FTLD, amyotrophic lateral
sclerosis with FTLD-TDP; FTLD-FUS, FTLD with fused in sarcoma protein
inclusions; FTLD-UPS, FTLD with tau- and TDP-43-negative ubiquitinated
inclusions; FTLD-ni, FTLD in the absence of significant neuropathological
inclusions), (B) pathogenic mutation associations with underlying
neuropathology (dashed-line separates less common molecular etiologies of
FTLD; MAPT, tau resulting in FTDP-17; C90rf72, pathogenic hexanucleotide
expansion resulting in FTLD and/or ALS associated with FTLD-TDP B; GRN,
progranulin resulting in FTLD-TDP type A; TARDP, TDP-43 resulting in ALS±
FTLD and less commonly FTLD; VCP, valosin-containing protein resulting in
inclusion body myopathy with Paget’s disease of bone and frontotemporal
dementia with FTLD-TDP subtype D; FUS, fused-in sarcoma protein resulting
in FTLD-FUS; and CHMP2B, charged mutlivesciular body protein 2B resulting
in FTLD-UPS), (C) clinicopathological correlations of FTLD (colored regions of
clinical syndromes represent relative percentages of neuropathological
subtypes found in autopsy studies; AD, Alzheimer’s disease; bvFTD,
behavioral variant of FTLD; PPA, primary progressive aphasia; svPPA,
semantic variant PPA; naPPA, nonfluent agrammatic variant PPA; lvPPA,
logopenic variant PPA; +ALS, co-morbid amyotrophic lateral sclerosis;
+EPS, co-morbid extra-pyramidal Parkinsonian symptoms: i.e., features of
akinetic-rigid syndromes of PSP or corticobasal syndrome).
genetic etiologies resulting in FTLD are exclusively associated
with specific underlying neuropathologies (Figure 1B), despite
heterogeneous expression of FTLD clinical syndromes, and
include pathogenic mutations in the gene for progranulin (GRN)
(Baker et al., 2006; Cruts et al., 2006), tau (MAPT) (Hutton et al.,
1998), and C9orf72 (C9orf72) (Dejesus-Hernandez et al., 2011;
Renton et al., 2011). Less common genetic etiologies of FTLD
include: valosin-containing protein (VCP) resulting in inclusion
body myopathy with Paget’s disease of bone and frontotemporal
dementia with FTLD-TDP subtype D neuropathology, TARDBP
coding for TDP-43 protein and causing ALS or ALS-FTLD (rarely
FTLD-TDP alone), CHMP2B coding for charged mutlivesciular
body protein 2B and resulting in FTLD-UPS, and mutations in
FUS causing FTLD-FUS (Figure 1B) (Mackenzie et al., 2010).
Clinically, FTLD can be broadly divided into two main
subtypes, those with predominant behavioral and social com-
portment disorder (behavioral-variant frontotemporal dementia,
bvFTD) (Rascovsky et al., 2011) and those with primary language
disturbances (primary progressive aphasia, PPA) (Mesulam,
1982, 2001). Among PPA patients, three subgroups have been
recently divided (Gorno-Tempini et al., 2011) into the logopenic
(lvPPA) (Gorno-Tempini et al., 2004, 2008), semantic (svPPA)
(Hodges and Patterson, 2007), and non-fluent aggramatic vari-
ant (naPPA) (Turner et al., 1996). Clinicopathological correla-
tions of these syndromes are complex (Josephs, 2008; Grossman,
2010). For example, large studies of autopsy-confirmed FTLD
(behavioral and aphasic variants) find roughly equal numbers of
FTLD-tau and FTLD-TDP (Hodges et al., 2004; Kertesz et al.,
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FIGURE 2 | FTLD-Tau and FTLD-TDP histology. Photomicrographs
of FTLD-tau (A–D) and FTLD-TDP (E–G) visualized with
immunohistochemistry (PHF-1 and pTDP 409/410 for tau and TDP,
respectively). (A) PSP frontal cortex with tau-positive tufted astrocytes
(arrows), (B) CBD temporal cortex with diffuse astrocytic plaques
(arrows) and neuronal tangles (asterisks), (C) Pick’s disease with round
tau-positive Pick bodies (asterisks) in the dentate nucleus of the
hippocampus, (D) FTDP-17 case with p.P301L pathogenic mutation with
tau-positive neuronal tangles (arrows) and diffuse neuropil threads in
temporal cortex, (E) FTLD-TDP subtype A with cytoplasmic neuronal
inclusions (asterisks) and short dystrophic neurites (arrows) in superficial
layers of frontal cortex, (F) FTLD-TDP subtype B with prominent
cytoplasmic inclusions (asterisks) in deep temporal cortical layer, and
(G) long dystrophic neurites (arrows) in superficial layers of mid-frontal
cortex of a patient with FTLD-TDP subtype C. Scale bar = 100μm.
2005; Knopman et al., 2005; Shi et al., 2005; Forman et al.,
2006). Furthermore, a primary neuropathological diagnosis of
Alzheimer’s disease (AD) has been found in up to 30% of autopsy-
confirmed clinically defined FTLD cohorts (Kertesz et al., 2005;
Knopman et al., 2005; Forman et al., 2006; Knibb et al., 2006).
Examination of focal presentations of AD found it to be the pri-
mary diagnosis in 7% of bvFTD, 44% of naPPA, 10% of svPPA,
and 50% of the extrapyramidal and cognitive disorder, corti-
cobasal syndrome (CBS) patients (Alladi et al., 2007). Others have
also found a substantial proportion of AD in PPA cases (Forman
et al., 2006; Knibb et al., 2006) especially in lvPPA (Grossman
et al., 2008; Mesulam et al., 2008; Grossman, 2010) and also CBS
(Lee et al., 2011). Thus, differentiation of AD and FTLD spectrum
disorders poses a serious diagnostic challenge for clinicians.
Within the FTLD neuropathological spectrum, examination
of the specific clinical subtypes finds varying degrees of asso-
ciation with FTLD-tau and FTLD-TDP (Figure 1C). FTLD-tau
has been overrepresented in some naPPA cohorts (Hodges et al.,
2004; Josephs et al., 2006a,b; Knibb et al., 2006; Snowden et al.,
2007; Mesulam et al., 2008; Grossman et al., 2012), especially
when associated with apraxia of speech (Josephs et al., 2006a;
Snowden et al., 2007) and svPPA has been predominantly asso-
ciated with TDP-43 pathology (Hodges et al., 2004; Josephs
et al., 2006a; Snowden et al., 2007; Grossman et al., 2008);
while bvFTD contains similar proportions of FTLD-tau and
FTLD-TDP (Forman et al., 2006; Josephs et al., 2006b; Snowden
et al., 2007). Extrapyramidal symptoms may predict a tauopathy
(Forman et al., 2006; Josephs et al., 2006b) while co-morbid ALS
is almost certainly due to TDP-43 aggregation (Shi et al., 2005;
Forman et al., 2006; Josephs et al., 2006b). Clinicopathological
associations from these large autopsy studies are summarized in
Figure 1C.
A major challenge in the development and implementation of
disease-modifying therapy in FTLD is the accurate identification
of the neuropathological diagnosis during life, including differen-
tiation fromAD, so that patients may be triaged to the appropriate
protein-targeted therapy (i.e., tau or TDP-43 targeted agents).
Biofluid biomarkers have the potential to optimize diagnos-
tic accuracy and detect disease earlier in the course of an illness
and possibly pre-symptomatically, such as prior to structural
changes of neurodegeneration seen on neuroimaging (Hu et al.,
2010a; Jack et al., 2010), making further exploration in this area
promising for the development of disease modifying treatments.
In addition, some clinical measures of disease progression in
FTLD, including functional scales, may be limited by floor- and
ceiling-effects (Knopman et al., 2008), so biofluid biomarkers are
potentially attractive surrogate end points for use in clinical trials
(Boxer et al., 2012b). The cerebrospinal fluid (CSF) is relatively
easy to obtain and contains a direct connection to the pathologi-
cal milieu in central nervous system, making it a desirable biofluid
for study. In this review we will discuss the current state of CSF
biomarker research in FTLD in terms of differentiation from AD
and future directions and challenges for the field in development
of FTLD-specific biomarkers.
ALZHEIMER’S DISEASE RELATED CSF BIOMARKERS: Aβ1−42
AND tau
STUDIES IN ALZHEIMER’S DISEASE
As a first step in biofluid-based biomarker assessment of neurode-
generative disease, it is valuable to distinguish broadly between
AD and FTLD. CSF values of themajor constituents of ADpathol-
ogy, tau and β-amyloid, (Aβ1−42) have been widely studied using
immune-based analytical platforms in AD and amnestic mild
cognitive impairment (MCI) patients, with lower Aβ1−42 values
and higher levels of total- and phosphorylated-tau (t-tau, p-tau)
compared with controls across multiple large studies (Shaw et al.,
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2009, 2011; DeMeyer et al., 2010; Trojanowski et al., 2010;Weiner
et al., 2010). Furthermore, our group has shown prognostic util-
ity of these markers by accurately predicting MCI conversion to
AD (Shaw et al., 2009; De Meyer et al., 2010).
The majority of atypical clinical presentations of AD in early-
onset patients consisting of predominantly visuo-spatial difficul-
ties (i.e., consistent with poster cortical atrophy) or asymmetric
apraxia/rigidity (i.e., consistent with CBS) may have a similar CSF
biomarker profile to that of typical amnestic-AD (De Souza et al.,
2011; Seguin et al., 2011), with a further elevated t-tau level in
one study (Koric et al., 2010). Elevated CSF t-tau and low Aβ1−42
levels have also been described in some PPA patients (i.e., lvPPA)
(Bibl et al., 2011; De Souza et al., 2011) most likely due to under-
lying AD neuropathology in these individuals; however, to our
knowledge no autopsy-confirmed studies of atypical clinical AD
presentations have been performed.
The exact relationship between AD neuropathologic change
(i.e., tau neurofibrillary pathology and Aβ1−42 extracellular
plaques) and observed measurement of these analytes in CSF is
unclear; however, the total tau level is thought to reflect underly-
ing neurodegeneration and neuron loss, as elevations are also seen
in other CNS insults (Otto et al., 1997; Hesse et al., 2000; Jin et al.,
2006; Ost et al., 2006; Krut et al., 2013). Lower Aβ1−42 CSF lev-
els may be the result of sequestration of soluble interstitial brain
Aβ1−42 into extracellular plaques as there is an inverse correlation
of CSF Aβ1−42 levels and the degree of cortical plaque pathol-
ogy (Tapiola et al., 2009; Patel et al., 2012; Seppala et al., 2012)
and in vivo neuroimaging evidence of amyloidosis (Fagan et al.,
2006). Phosphorylated epitopes of tau (p-tau) can bemeasured in
CSF as well; while most phospho-epitopes of tau are also found in
healthy non-diseased brains and are not AD-specific, pathologi-
cal tau species overall are highly phosphorylated in AD (Matsuo
et al., 1994) and this altered state reflects the elevated levels of
p-tau seen in AD. The most commonly studied p-tau epitopes are
serine 181 (p-tau181) (Vanmechelen et al., 2000), and threonine
231 (p-tau231) (Buerger et al., 2002a,b).
STUDIES IN FRONTOTEMPORAL LOBAR DEGENERATION
FTLD is not characterized pathologically by cerebral Aβ1−42 amy-
loidosis, and only FTLD-tau is characterized by significant tau
inclusions. From this perspective, measures of CSF t-tau and
Aβ1−42 may have helpful diagnostic utility in excluding AD
neuropathology. Indeed, in clinically-defined cohorts AD cases
have higher levels of t-tau, p-tau181 and lower levels of Aβ1−42
compared to FTLD and controls in group-wise comparisons
(Blennow et al., 1995; Arai et al., 1997; Green et al., 1999; Sjogren
et al., 2000a, 2001; Vanmechelen et al., 2000; Riemenschneider
et al., 2002; Clark et al., 2003; Pijnenburg et al., 2004, 2007;
Schoonenboom et al., 2004, 2012; Engelborghs et al., 2006; Bibl
et al., 2007, 2011; Kapaki et al., 2008; Verwey et al., 2010; De Souza
et al., 2011; Gabelle et al., 2011; Van Harten et al., 2011).
A major challenge in FTLD CSF biomarker studies is the
heterogeneity of the condition (Figure 1), making autopsy-
confirmation of diagnostic classification a crucial issue. As men-
tioned previously, up to 30% of clinically-defined FTLD cohorts
may have underlying AD neuropathologic change as the etiol-
ogy of their symptoms (Kertesz et al., 2005; Knopman et al.,
2005; Forman et al., 2006; Knibb et al., 2006) and contamination
with these atypical AD cases could influence results significantly.
Indeed, examination of diagnostic accuracy of CSF t-tau and
Aβ1−42 in a large autopsy-confirmed dementia cohort found
that use of the clinical diagnosis, rather than neuropathologi-
cal diagnosis as the gold standard for biomarker performance
resulted in a 10–20% underestimation of biomarker accuracy
(Toledo et al., 2012). Furthermore, since 1995 there has been
over a 10-fold increase in the number of FTLD manuscripts pub-
lished (NLM/NIH, 2012) and due to this exponential increase
in research in the field and our expanding knowledge of FTLD,
clinical criteria (Gorno-Tempini et al., 2011; Rascovsky et al.,
2011) have evolved resulting in refinement of our clinical def-
initions. Indeed, the emergence of the new clinical variant of
PPA, lvPPA (Gorno-Tempini et al., 2008, 2011), which is most
often associated with AD neuropathology (Mesulam et al., 2008;
Rabinovici et al., 2008; Grossman, 2010) (Figure 1C), and there-
fore suggested to be excluded from FTLD clinical trials (Knopman
et al., 2008), could influence group-wise CSF tau and Aβ1−42
results. Thus, the makeup of clinical cohorts used in earlier stud-
ies may not be entirely translatable to newer studies, limiting the
meaningful interpretation of the literature of clinically-derived
cohorts.
As such, study of autopsy/genetic-confirmed cases has been
a focus for our center. In an early study of autopsy-confirmed
cases by our group, AD was differentiated from a mixed demen-
tia cohort (including 13 FTLD cases) with reasonable sensitivity
(72%) and specificity (69%) using CSF t-tau levels (Clark et al.,
2003). Focused analysis of FTLD (with autopsy confirmation in
9 cases) in a later study found lower levels of t-tau and higher
levels of Aβ1−42 than AD, and roughly 30% of FTLD cases had sig-
nificantly decreased t-tau from controls (Grossman et al., 2005).
In a follow-up large autopsy/genetically confirmed FTLD series
(n = 30) t-tau levels were significantly lower in FTLD than AD,
while similar to controls on group-wise comparison; individual-
case analysis revealed that a considerable subset of FTLD patients
had markedly low t-tau values (Bian et al., 2008). Interestingly,
FTLD cases with substantially lower t-tau levels included both
FTLD-tau and FTLD-TDP (Bian et al., 2008), although a non-
significant trend was found for lower t-tau in FTLD-tau (Hu et al.,
2011). Furthermore, FTLD was differentiated from AD with high
accuracy using the t-tau/Aβ1−42 ratio; that is, FTLD cases had a
lower ratio (lower t-tau and higher Aβ1−42) (Bian et al., 2008).
Measurement of these analytes in the CSF in most stud-
ies utilizes one of two immune-based platforms: enzyme-
linked immunosorbent assay (ELISA; Innotest, Innogenetics),
and a multiplex assay based on flow-cytometry of antibody-
coated fluorescent beads (INNO-BIA AlzBio3 xMAP; Luminex,
Innogenetics). Absolute values obtained from these platforms dif-
fer because the coefficient of variance (%CV) with the xMAP
Luminex platform is much narrower than with ELISA, but they
are highly correlated (Olsson et al., 2005; Lewczuk et al., 2009;
Fagan et al., 2011; Wang et al., 2012) and have similar lev-
els of diagnostic accuracy for AD (Fagan et al., 2011; Wang
et al., 2012) and differentiating AD from FTLD (Toledo et al.,
2012). Thus, values from one platform can be effectively trans-
formed into equivalent units of the other using a conversion
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factor (Fagan et al., 2011; Wang et al., 2012). Indeed, we were able
to transform values obtained from ELISA to equivalent xMAP
units using linear regression to create a larger autopsy/genetic-
confirmed FTLD dataset and help confirm our pervious observa-
tions of the diagnostic utility of the t-tau/Aβ1−42 ratio to differen-
tiate FTLD from AD (Irwin et al., 2012b). Maximizing available
data is crucial for these extremely valuable and well-annotated
research samples. In summary, in multiple large-scale autopsy-
confirmed studies we have demonstrated the diagnostic utility of
CSF t-tau, p-tau, and Aβ1−42 in differentiation of AD and FTLD
(Bian et al., 2008; Irwin et al., 2012b; Toledo et al., 2012).
Few other CSF studies have used autopsy-confirmed cohorts
of FTLD patients (Table 1). One study included 10 autopsy-
confirmed FTLD patients and found similar results of lower t-tau
and p-tau181 levels in FTLD compared with AD, with high diag-
nostic accuracy of p-tau181 (Koopman et al., 2009). Another
study including 12 confirmed FTLD patients described “slightly
elevated tau levels” in several patients compared to an age-
dependent reference range and low compared to the majority
of AD cases (Brunnstrom et al., 2010). Neuropathological sub-
groups of FTLD (FTLD-TDP, n = 5 and FTLD-tau, n = 7) had
similar mean values, with 4/12 patients below the reference limit
by >70 pg/ml (Brunnstrom et al., 2010). Thus, this study also
found a subset of individual FTLD patients with lower than nor-
mal t-tau levels. The diagnostic utility of t-tau/Aβ1−42 in differen-
tiating FTLD was not systematically explored in this small group
of AD cases (n = 8). Finally, to our knowledge the only additional
studies utilizing autopsy-confirmed FTLD cohorts included a
small number of FTLD cases (<10) in a non-AD category, with
no direct comparison of FTLD and AD (Engelborghs et al., 2008;
Tapiola et al., 2009; Schoonenboom et al., 2012). Thus, further
study is required in large prospective, autopsy-confirmed samples
to confirm our observations.
The higher Aβ1−42 in FTLD compared to AD most likely
reflects the absence of significant cerebral amyloidosis while the
biological basis for observed lowCSF t-tau in some FTLD patients
is uncertain. One possibility is related to cortical tau depletion
(Zhukareva et al., 2001, 2003; Grossman et al., 2005) through
sequestration into the neuronal and glial inclusions in the absence
of significant extracellular tau pathology (FTLD-tau) Dickson,
2004, such as extracellular “ghost tangles” as seen in AD (Schmidt
et al., 1988), or altered post-translational stability of tau in FTLD-
TDP (Zhukareva et al., 2001, 2003); furthermore, CSF t-tau does
appear related to underlying FTLDpathophysiology as t-tau levels
Table 1 | Comparative studies of CSF biomarkers in autopsy/genetic-confirmed FTLD and AD cohorts.
Study Patients Aβ1−42 t-tau p-tau181 Diagnostic accuracy (AD vs. FTLD)
Clark et al., 2003 (10) FTLD(74) AD*73 (4) CN AD< FTLD, CN CN<FTLD<AD NA No statistical analysis of FTLD diagnostic
accuracy performed
Grossman et al.,
2005
73 (11) FTLD(17) AD13 CN AD< FTLD, CN CN, FTLD<AD CN, FTLD<AD t-tau
AUC = 0.86, sens = 74%, spec = 82.4%
Bian et al., 2008 (30) FTLD(19) AD13 CN AD< FTLD, CN CN, FTLD<AD NA t-tau/Aβ1−42
AUC = 0.93, sens = 78.9%, spec = 96.6%
Engelborghs et al.,
2008
(2) FTLD(73) AD*100 CN NA NA NA No statistical analysis of FTLD diagnostic
accuracy performed
Koopman et al.,
2009
(10) FTLD(95) AD AD< FTLD FTLD<AD FTLD<AD p-tau181
AUC = 0.85, sens = 91%, spec = 80%
Tapiola et al., 2009 (9) FTLD(83) AD NA NA NA No statistical analysis of FTLD diagnostic
accuracy performed
Brunnstrom et al.,
2010
(12) FTLD(8) AD* NA NA NA No statistical analysis of FTLD diagnostic
accuracy performed
Irwin et al., 2012b (20) FTLD(41) AD* NA NA NA t-tau/Aβ1−42
AUC = 0.99, sens = 90–100%, spec =
90–96%
Toledo et al., 2012 (71) AD(29) FTLD66 CN AD< FTLD<CN CN, FTLD<AD CN, FTLD<AD t-tau/Aβ1−42 (ELISA)
AUC = 0.96, sens = 90, spec = 82%
p-tau181/Aβ1−42 (xMAP)
AUC = 0.98, sens = 100%, spec = 88%
Other diagnostic groups that may be present in some studies are omitted and only direct comparisons of FTLD group to AD or CN are reported. “<” or “>” denotes
significant difference between groups and “,” denotes non-significant difference between groups, () denotes autopsy/genetic confirmed cohort.
CN, non-demented controls; *, AD group contains cases with co-morbid Lewy Body or Vascular Disease; NA, Not assessed; AUC, Area under the curve for receiver
operating curve analysis; ELISA, enzyme-linked immunosorbent assay; xMAP, luminex multiplex assay.
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in FTLD patients correlated to areas of frontal and temporal cor-
tical atrophy on magnetic resonance imaging (MRI) (Grossman
et al., 2005; McMillan et al., 2013). Further study of CSF protein
dynamics in animalmodels of diseasemay help clarify these seem-
ingly discordant associations of low tau levels with underlying
neuropathology in FTLD-tau and FTLD-TDP.
Despite the clear distinction of t-tau and Aβ1−42 levels between
AD and FTLD, there is more variability in the literature for
the relationship of these markers in FTLD compared with
non-demented controls (Table 1). There are several reasons for
these discrepancies; first, even in most autopsy-based studies,
autopsy data on controls is lacking (Table 1) and a significant
proportion of non-demented elderly can have underlying AD
neuropathology (Davis et al., 1999), and thus influence CSF ana-
lyte measures. Next, even with pathologic confirmation, patient
classification in FTLD is challenging, as another potential con-
founding issue is the presence of mixed pathologies in dementia
patients. Indeed, our group has shown in a large autopsy-
confirmed sample that mixed pathology is present in roughly
30% of cases, and that FTLD patients with significant AD neu-
ropathologic change can influence the CSF t-tau and Aβ1−42
levels, causing higher t-tau and lower Aβ1−42 in cases with mixed
FTLD and AD pathology compared to “pure” FTLD (Toledo et al.,
2012). Additionally, a recent largely clinically-defined cohort
study found an AD CSF biomarker profile in 30% of FTLD
(Schoonenboom et al., 2012) which may be due, in part, to
mixed pathology or inclusion of atypical AD cases mimicking
the FTLD clinical syndrome (Toledo et al., 2012). Thus, the use
of autopsy-confirmed samples is essential for in-depth study and
validation of the diagnostic accuracy of potential biomarkers
in FTLD.
Finally, variability in measurement between studies is another
potential issue as significant variation between centers in abso-
lute values measured in “spiked” pooled CSF control sam-
ples with known concentrations of analyte has been described
(Shaw et al., 2011). These discrepancies are most likely due to
sources of variation in CSF collection, handling and storage
(pre-analytical), equipment, reagents and methods of analysis
(analytical), and data management and interpretation (post-
analytical) (Mattsson et al., 2011). For these reasons, large
scale studies of measurement precision of these analytes and
coordinated multi-center quality control programs with stan-
dard operating procedures to minimize these sources of varia-
tion have been conducted (Mattsson et al., 2011; Shaw et al.,
2011).
Despite these issues, we have demonstrated (Bian et al., 2008;
Irwin et al., 2012b; Toledo et al., 2012) that these AD-specific
analytes (t-tau to Aβ1−42 ratio) may perform within the range
of sensitivity and specificity (>80%) for use in clinical trials
(Trojanowski and Growdon, 1998) to differentiate FTLD from
AD; however, these analytes are not as effective for differentiation
of FTLD from normal controls (Bian andGrossman, 2007; Toledo
et al., 2012). Although patients may present with decompensated
psychiatric issues or other non-progressive non-degenerative eti-
ologies resembling FTLD (phenocopy syndrome) (Kipps et al.,
2010), these patients may be identified with serial clinical exams
and neuroimaging (Kipps et al., 2010). The more urgent need
is for FTLD-specific biomarkers and those that can differentiate
between the two major neuropathologic subtypes (FTLD-tau and
FTLD-TDP) (Hu et al., 2011).
FUTURE DIRECTIONS
FURTHER STUDY OF CSF tau AND Aβ1−42
Previous work in large cross-sectional studies in AD suggests
a temporal progression of dynamic biomarker change in AD
(Jack et al., 2010, 2012), as Aβ1−42 amyloidosis, and resultant
lower CSF Aβ1−42, is thought to occur decades before clinical
symptoms emerge in AD, while increased CSF t-tau is thought
to be a later event in disease progression and correlates more
closely with cognitive decline. It is likely that t-tau, p-tau and
potential novel CSF biomarkers could display similar changes
throughout the course of disease in FTLD and could correlate
with clinical symptoms. Few studies have examined the change in
CSF biomarkers over time or their relation to clinical symptoms.
One study included a follow up CSF analysis in one FTLD-
tau patient, with similar t-tau and Aβ1−42, roughly 18 months
between CSF collections (Brunnstrom et al., 2010). Interestingly,
a recent study of bvFTD patients found a significant correlation
with Aβ1−42 levels and cognitive performance, even after removal
of patients with CSF profile suggestive of AD neuropathology
(Koedam et al., 2012). These results could suggest an influence
of co-morbid AD neuropathology; however autopsy information
in these cases was lacking. Other studies in clinical series with-
out autopsy confirmation found no association of these markers
and clinical measures or disease severity (Riemenschneider et al.,
2002; Engelborghs et al., 2006; De Souza et al., 2011). Further
study of clinical correlates of CSF biomarkers and longitudinal
profiles of CSF analyte change throughout the course of disease
will be helpful.
Similar to the dominantly-inherited AD network (DIAN) ini-
tiative to study patients with known pathogenic mutations to
cause AD (Bateman et al., 2012), study of prodromal FTLD
patients with pathogenic mutations may provide additional
insights into the temporal sequence of biomarkers in FTLD
(Boxer et al., 2012a). Furthermore, CSF analyte levels in symp-
tomatic patients with genetic forms of FTLD have not been
explored in detail and could potentially differ from sporadic
cases. Indeed, we found a more rapid rate of progression in
cognitive measures corresponding to more severe neurodegener-
ation in C9orf72-associated FTLD (Irwin et al., 2013) and others
have described unique neuroimaging patterns of atrophy across
different genetic forms of FTLD (Whitwell et al., 2012). This
evidence of biologic differences in genetic and sporadic FTLD
suggest alterations in CSF biomarker profiles are also a possibil-
ity, although one study found similar levels of CSF tau and Aβ1−42
in genetically-confirmed FTDP-17 (n = 9) compared to sporadic
FTLD (n = 17) (Rosso et al., 2003).
DEVELOPMENT OF FTLD-SPECIFIC BIOMARKERS
In the context of disease-modifying therapies targeting a spe-
cific histopathologic abnormality, an important goal is to dis-
tinguish between FTLD due to TDP-43 and FTLD due to tau.
Exploratory analyses for novel biomarkers that have diagnostic
utility in FTLD are ongoing and include several basic approaches.
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First, measurement of biologically relevant molecules is the most
straightforward approach, as tau and Aβ1−42 have been success-
ful biomarker candidates in AD. Using this rationale, the two
most obvious candidates for FTLD-specific biomarkers are TDP-
43 progranulin. Indeed, TDP-43 has been detected in human
CSF (Steinacker et al., 2008; Kasai et al., 2009) and serum
(Foulds et al., 2008), suggesting elevated levels may occur in
some patients with TDP-43 proteinopathies, but initial stud-
ies show limited diagnostic accuracy. Low serum progranulin
may identify FTLD patients with a pathogenic GRN mutation
resulting in progranulin haploinsufficiency (Ghidoni et al., 2008),
which could be useful in monitoring potential progranulin-
replacing therapies in development for FTLD (Boxer et al.,
2012b).
Other biologically relevant potential biomarkers for FTLD
include specific isoforms or neoepitopes of tau. Tau undergoes
multiple post-translational modifications thought to contribute
to tangle formation. Indeed, we found acetylation of tau at a
specific residue in the microtubule-binding domain (MTBD)
to be exclusively found in tauopathies, providing promise for
this epitope as a useful marker of AD and FTLD-tau (Cohen
et al., 2011; Irwin et al., 2012a). Translating these immunohis-
tochemical observations to clinical assays may prove difficult,
as levels of tau in CSF are near the lower limits of biologic
detection (Hampel et al., 2010) limiting the further identifica-
tion of a specific subset of tau in the form of a neoepitope;
although one group has found promising evidence for diag-
nostic utility of specific C-truncated isoforms of tau in PSP
through immunoprecipitation and western blotting techniques
(Borroni et al., 2008, 2009) and others have developed assays to
measure 3- and 4R tau in CSF (Luk et al., 2012). Alternatively-
truncated forms of Aβ1−42 may also have diagnostic importance
in FTLD (Pijnenburg et al., 2007; Bibl et al., 2011, 2012; Gabelle
et al., 2011) and cytoskeletal proteins, such as neurofilament
have also been explored (Sjogren et al., 2000b; De Jong et al.,
2007). These potential biomarkers warrant further study and
validation.
Another, possible approach is to screen a large number of
potential analytes without an a priori biologic rationale in a pro-
teomic analysis of CSF in FTLD. Indeed, using an immune-based
multiplex approach our group found promising CSF biomarker
candidates to differentiate FTLD-TDP and FTLD-tau with high
sensitivity and specificity, but these candidate analytes need fur-
ther study to confirm their utility as FTLD biomarkers (Hu et al.,
2010b). Finally, other non-immune basedmethods, such as mass-
spectrometry are also being explored to identify novel biofluid
biomarkers in FTLD (Mattsson et al., 2008).
Potential FTLD-specific biofluid biomarkers will be faced with
the same challenges of testing reliability and sources of varia-
tion (i.e., analytical, pre-/post-analytical) currently experienced
by CSF t-tau and Aβ1−42 measurements. As such, coordinated
and cooperative efforts between multiple centers will undoubt-
edly be necessary to help validate potential FTLD-specific CSF
biomarkers prior to clinical use.
Most likely, a multimodal assessment incorporating poten-
tial novel biofluid biomarker values with clinical, neuroimaging
and genetic markers may be the most effective approach to
accurately identify FTLD subtypes. Neuropsychological testing
can help differentiate AD from FTLD (Rascovsky et al., 2008;
Libon et al., 2011) as routine cognitive measures may not be sen-
sitive enough to detect the behavioral and language deficits in
FTLD. Indeed, our group has explored quantitative approaches
to language (Ash et al., 2006, 2009; Gunawardena et al., 2010)
and social cognition (Massimo et al., 2009, 2013; Grossman et al.,
2010; Eslinger et al., 2012; McMillan et al., 2012b) to exam-
ine brain-behavior relationships and improve diagnostic accuracy
in FTLD. Neuroimaging is another potential method with diag-
nostic utility alone, or as an adjunct to clinical and biofluid
biomarkers in FTLD; we have found combining neuropsycho-
logical testing and MRI can improve diagnostic accuracy in PPA
(Hu et al., 2010c); and others find combination of CSF tau
isoform levels and midbrain atrophy improve identification of
PSP (Borroni et al., 2010). Multiple modalities of MRI meth-
ods, including diffusion-tensor imaging (DTI) of white matter
may help identify FTLD patients in dementia cohorts. We have
demonstrated increased diagnostic sensitivity to differentiate AD
from FTLD cases using a combination of gray matter (GM) den-
sity and DTI measures (McMillan et al., 2012a). In addition, we
have also discovered promising diagnostic utility for differenti-
ating FTLD-tau and FTLD-TDP using DTI (unpublished data).
Cortical atrophy and CSF biomarker levels appear to be highly
correlated as we have recently demonstrated that GM density
could predict CSF t-tau and Aβ1−42 levels, and these predicted
values could accurately distinguish AD and FTLD (McMillan
et al., 2013). These results indicate that MRI could potentially
serve as a surrogate for CSF, which would have significant util-
ity for patients where lumbar puncture would be difficult or for
clinical trial endpoints where repeated lumbar puncture may be
needed. Finally, recent genome-wide association studies (GWAS)
have found risk alleles associated with FTLD-TDP (Van Deerlin
et al., 2010) and FTLD-tau (Hoglinger et al., 2011). Further
knowledge of clinical, neuroimaging, and biofluid correlates of
these risk alleles in FTLD could provide further useful diagnos-
tic and prognostic information. Thus, comparative studies of
clinical, genetic, biofluid, and neuroimaging biomarkers in lon-
gitudinally followed, well-annotated, autopsy-confirmed subjects
will be a powerful method for improving our understanding of
the pathophysiology of FTLD and further directing diagnostic
and treatment efforts.
SUMMARY
CSFmeasurements of Aβ1−42, t-tau, and p-tau in FTLD differ sig-
nificantly from the abnormal levels seen in AD, and in a subset of
both FTLD-tau and FTLD-TDP there are extremely low levels of
t-tau of unclear etiology. These properties allow for accurate dis-
tinction of FTLD from AD in autopsy-confirmed cohorts, while
FTLD-specific markers are still lacking.
As we move toward therapies that impact the progression of
the disease and target the underlying pathophysiology in FTLD
and other neurodegenerative disorders it will be essential for clin-
icians to view these disorders as clinicopathological entities with
the underlying neuropathological substrate in mind. Indeed, new
clinical criteria for AD incorporate this ideology with the desig-
nation of “pre-symptomatic AD” (Sperling et al., 2011). In the
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study of the complex clinicopathological spectrum of FTLD dis-
orders, where heterogeneity is the rule, useful markers to develop
homogenous clinical, genetic, and neuropathologic subgroups
will be crucial to further our goals toward meaningful treatments
that could potential slow disease progression and limit patient
disability.
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